Sugi Predict

Sugi Predict / Compounds / SCHEMBL6944706

SCHEMBL6944706

SCHEMBL6944706

COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1c(F)cccc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.64
▸ CYP2C9 P11712 5/20 0.57
▸ MEN1 O00255 4/20 0.57
▸ CYP1A2 P05177 4/20 0.57
▸ CYP3A4 P08684 4/20 0.57
▸ CYP2C19 P33261 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ LMNA P02545 3/20 0.57
▸ TSHR P16473 3/20 0.57
▸ CYP2D6 P10635 2/20 0.57
▸ NFKB1 P19838 2/20 0.57
▸ THPO P40225 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ CACNA1F O60840 3/20 0.47
▸ CACNA1D Q01668 3/20 0.47
▸ CACNA1S Q13698 3/20 0.47
▸ CACNA1C Q13936 3/20 0.47
▸ TP53 P04637 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ HIF1A Q16665 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949599 0.97 ALOX15 (0.61) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL6948648 0.93 CYP1A2 (0.62) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL6945772 0.89 ALOX15 (0.68) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL6947901 0.83 CYP2C9 (0.59) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL7410229 0.83 CYP2C9 (0.66) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL6950267 0.83 CYP1A2 (0.58) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL11450610 0.82 CYP2C9 (0.57) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL6952565 0.81 ALOX15 (0.61) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL11451831 0.81 CYP2C9 (0.62) ALOX15CYP2C9MEN1CYP1A2CYP3A4
SCHEMBL11497442 0.81 CYP2C9 (0.62) ALOX15CYP2C9MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0657432-B1 Phenyl-substituted 1,4-dihydropyridines with cerebral activity BAYER AG (DE) 2003-03-12 — — EP claimed
US-6630494-B2 Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders BAYER AKTIENGESELLSCHAFT (DE) 2003-10-07 — — US disclosed
US-20010034451-A1 Phenyl-substituted 1,4-dihydropyridines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2001-10-25 — — US disclosed
US-6239155-B1 TREATMENT OF CENTRAL DEGENERATIVE DISORDERS, AS DEMENTIAS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR AMYOTROPHIC LATERAL SCLEROSIS, MEMORY IMPAIRMENT, DEPRESSIONS, MIGRAINE, OF NEUROPATHIES, METABOLIC DISORDERS SUCH AS DIABETES BAYER AKTIENGESELLSCHAFT (DE) 2001-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034451-A1 Phenyl-substituted 1,4-dihydropyridines GRIK4, PKM, PDK4 ALOX15 2928/4885CYP2C9 783/4885MEN1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.